Short-term results of the new version of toric implantable collamer lens for moderate to high myopic astigmatism

Poster Details

First Author: P.Fernandes PORTUGAL

Co Author(s):    J. Alfonso   C. Lisa   R. Mont        

Abstract Details

Purpose:

To assess the predictability, efficacy, safety, and stability of the new version collagen copolymer toric phakic intraocular lens (TICL V4b) implantation to correct astigmatism.

Setting:

Fernįndez-Vega Ophthalmological Institute. Oviedo. Spain

Methods:

This study comprised 24 eyes of 12 patients that had implantation of TICL V4b for moderate to high myopic astigmatism. The uncorrected (UDVA) and corrected (CDVA) distance visual acuities, refraction, pIOL vault, and adverse events were evaluated at 3 months.

Results:

Preoperatively, the mean sphere was ?10.69 diopters (D) ± 3.36 (SD) (range ?5.00 to ?17.00 D) and the mean cylinder, 3.00± 0.98 D (range 1.00 to 5.00 D). At 3 months, the mean Snellen decimal UDVA was 0.91 ± 0.12 and the mean CDVA, 0.96 ± 0.09; 91.7% of eyes had a UDVA of 20/25; 41.7% of eyes gained 1 or more lines of CDVA. Predictable was very high for spherical equivalent (SE) (r2 = 0.99) and astigmatic components J0 (r2 = 0.96) and J45 (r2 = 0.97). All were within ±0.50 D of the attempted SE and for J0, 79.2% of eyes were within ±0.50 D and for J45, 87.5% of eyes; all eyes were within ±1.00 D. The efficacy and safety index was 1.06 and 1.12, respectively. No eye had pIOL rotation greater than 30 degrees. The mean central vault was 585±133µm (95% CI: 526 to 644 µm); no eyes had vault ? 300µm and between 300 and 750 µm in 90% of eyes.

Conclusions:

This short-term study confirms the new version of the TICL is safe, predictable, and effective for moderate to high astigmatic correction. Important safety concerns were not identified. FINANCIAL DISCLOSURE?: No